Abivax SA (DE:2X1)
XETRA:2X1
2X1 Stock Chart & Stats
€100.00
-€0.05(-0.72%)
At close: 4:00 PM EST
€100.00
-€0.05(-0.72%)
Day’s Range― - ―
52-Week Range€4.64 - €132.20
Previous CloseN/A
Volume500.00
Average Volume (3M)891.00
Market Cap
€7.89B
Enterprise Value€7.40B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€32.09M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Jun 08, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding79,291,190
10 Day Avg. Volume1,388
30 Day Avg. Volume891
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.00Price Target Upside30.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)€3.40M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetBalance sheet strength in 2025 (debt ~7% of equity and a material equity increase) materially raises funding flexibility. This durable cushion reduces near-term solvency risk and gives management more time to advance clinical programs without immediate distress-driven asset sales or rushed dilution.
High Historical Gross MarginsWhen revenue was present, gross margins were near 100%, indicating attractive unit economics typical of proprietary small-molecule therapeutics. If clinical development succeeds, those high margins imply strong commercial profitability potential versus peers, supporting long-term return generation once commercialized.
Focused Clinical-stage PipelineA concentrated R&D focus on obefazimod for chronic inflammatory indications creates clear strategic alignment and resource concentration. This specialization can accelerate trial design and regulatory planning, preserving managerial expertise and capital efficiency versus a diffuse pipeline over the next several months.
Bears Say
Persistent Cash BurnChronic negative operating and free cash flow, with 2025 FCF around -162M, signals ongoing cash consumption to fund trials. This structural burn necessitates repeated external financing, raising dilution risk and diverting management focus to capital raises rather than purely clinical execution over the medium term.
Zero 2025 RevenueThe drop to zero reported revenue in 2025 means the company lacks commercial income to offset R&D and G&A. Reliance on non-operating funding rather than product receipts increases execution risk and makes the business model contingent on successful trial outcomes and future commercialization.
Widening Net And Operating LossesDeepening operating and net losses across 2020–2025 reflect scale mismatch between costs and any revenue. Persistent negative profitability undermines internal capital generation, pressures returns metrics long-term, and increases dependence on volatile external capital markets to sustain operations and trials.
Abivax SA News
2X1 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €4.63 and its highest was €132.20 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.89B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Jun 08, 2026 which is in 61 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Mar 23, 2026. The company reported -€1.04 earnings per share for the quarter, beating the consensus estimate of -€1.161 by €0.121.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.81.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,291,190 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.04 in its last earnings report, beating expectations of -€1.161. Following the earnings report the stock price went down -3.937%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in DE:2X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
2X1 Stock 12 Month Forecast
Average Price Target
€130.00
▲(30.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---